SynthesisFrontiers in medicine2026

Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials.

Maan H Harbi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.